PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.12%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-7.85%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-18.15%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-18.15%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-18.18%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-13.29%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-11.46%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-3.18%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-3.78%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-36.67%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
20.40%
OCF growth under 50% of JHX's 50.90%. Michael Burry might suspect questionable revenue recognition or rising costs.
20.85%
FCF growth under 50% of JHX's 193.61%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.08%
Inventory is declining while JHX stands at 15.99%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.35%
Negative asset growth while JHX invests at 3.74%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-1.05%
We have a declining book value while JHX shows 6.94%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
9.58%
Debt growth far above JHX's 5.50%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-42.94%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.